"10.1371_journal.pone.0132117","plos one","2015-07-22T00:00:00Z","Stephanie K Venn-Watson; Celeste Parry; Mark Baird; Sacha Stevenson; Kevin Carlin; Risa Daniels; Cynthia R Smith; Richard Jones; Randall S Wells; Sam Ridgway; Eric D Jensen","Translational Medicine and Research Program, National Marine Mammal Foundation, San Diego, California, United States of America; Kennedy Krieger Institute, Baltimore, Maryland, United States of America; Chicago Zoological Society c/o Mote Marine Laboratory, Sarasota, Florida, United States of America; U.S. Navy Marine Mammal Program, San Diego, California, United States of America","Conceived and designed the experiments: SVW. Performed the experiments: SVW CP MB SS RD CRS RJ RSW EDJ. Analyzed the data: SVW CP KC RD RJ RSW SR. Wrote the paper: SVW CP RD RJ RSW SR EDJ.","Scientific findings from this study are part of a pending United States Utility Patent (Serial No.14/591,660), Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome, filed by the United States Navy. As a result of the reported discovery and pending patent, a small business owned by the lead author (SVW), Epitracker, LLC, has acquired a license to practice this discovery. The pending patent and license are a result of this studys discovery. The study design, data analysis and interpretation, and a draft manuscript were completed before the patent application and license. The authors ensure that the stated potential competing interests did not interfere with this studys original design or outcome and that this does not alter the authors adherence to PLOS ONE policies on sharing data and materials. To ensure transparency, raw data from the original laboratory results and details of the study design have been provided to DRYAD (doi:10.5061/dryad.jm57v).","2015","07","Stephanie K Venn-Watson","SKVW",11,TRUE,1,9,7,7,TRUE,TRUE,FALSE,0,NA,FALSE
